Suchen
60 Degrees Pharmaceuticals Inc
SXTPZur Watchlist hinzufügen
1.390USD
-0.070-4.79%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
3.67MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über 60 Degrees Pharmaceuticals Inc Unternehmen
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
60 Degrees Pharmaceuticals Inc Informationen
BörsenkürzelSXTP
Name des Unternehmens60 Degrees Pharmaceuticals Inc
IPO-datumJul 12, 2023
CEODow (Geoffrey S)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeJul 12
Addresse1025 Connecticut Avenue Nw
StadtWASHINGTON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20036
Telefon12023275422
Websitehttps://60degreespharma.com/
BörsenkürzelSXTP
IPO-datumJul 12, 2023
CEODow (Geoffrey S)
Führungskräfte von 60 Degrees Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.78K
+32.32%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
--
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Mr. Paul Field
Mr. Paul Field
Independent Director
Independent Director
59.00
--
Mr. Patrick Gaynes
Mr. Patrick Gaynes
Investor Relations Officer
Investor Relations Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey S. Dow, Ph.D.
Dr. Geoffrey S. Dow, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.78K
+32.32%
Ms. Cheryl Xu
Ms. Cheryl Xu
Director
Director
3.95K
--
Mr. Tyrone Miller
Mr. Tyrone Miller
Chief Financial Officer
Chief Financial Officer
1.32K
--
Ms. Kristen Landon
Ms. Kristen Landon
Chief Commercial Officer
Chief Commercial Officer
1.14K
--
Mr. Charles W. Allen
Mr. Charles W. Allen
Independent Director
Independent Director
59.00
--
Dr. Stephen Toovey
Dr. Stephen Toovey
Independent Director
Independent Director
59.00
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Kathmere Capital Management
5.49%
Orca Capital GmbH
1.58%
UBS Financial Services, Inc.
1.19%
Dow (Geoffrey S)
0.64%
Knight Therapeutics, Inc.
0.32%
Andere
90.79%
Aktionäre
Aktionäre
Anteil
Kathmere Capital Management
5.49%
Orca Capital GmbH
1.58%
UBS Financial Services, Inc.
1.19%
Dow (Geoffrey S)
0.64%
Knight Therapeutics, Inc.
0.32%
Andere
90.79%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
8.27%
Individual Investor
0.89%
Corporation
0.32%
Research Firm
0.21%
Investment Advisor/Hedge Fund
0.12%
Hedge Fund
0.06%
Andere
90.13%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
27
228.38K
8.66%
+141.57K
2025Q4
25
52.23K
4.06%
-28.54K
2025Q3
22
451.55K
11.00%
+385.44K
2025Q2
28
103.95K
3.22%
+2.41K
2025Q1
28
93.99K
6.38%
-12.96K
2024Q4
26
104.62K
14.10%
+11.58K
2024Q3
25
101.03K
25.05%
+54.30K
2024Q2
23
54.29K
27.13%
-3.10K
2024Q1
19
57.35K
31.08%
+1.78K
2023Q4
19
60.17K
63.69%
+30.80K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Orca Capital GmbH
41.56K
1.58%
+41.56K
--
Jul 16, 2025
Dow (Geoffrey S)
11.36K
0.43%
+5.66K
+99.32%
Dec 15, 2025
Knight Therapeutics, Inc.
8.47K
0.32%
+3.67K
+76.27%
Sep 30, 2024
Xu (Cheryl)
3.95K
0.15%
+1.75K
+79.40%
Aug 26, 2025
Geode Capital Management, L.L.C.
3.11K
0.12%
--
--
Dec 31, 2025
Tower Research Capital LLC
1.69K
0.06%
+900.00
+114.65%
Dec 31, 2025
Miller (Tyrone)
1.32K
0.05%
--
--
Aug 26, 2025
Landon (Kristen)
1.14K
0.04%
--
--
Aug 26, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Datum
Ex-Dividendentag
Art
Verhältnis
Jan 15, 2026
Merger
4→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Feb 20, 2025
Merger
5→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
Aug 06, 2024
Merger
12→1
